Boston Scientific Says PREVAIL Results Affirm Safety of Watchman LAA Anti-Stroke Device
This article was originally published in The Pink Sheet Daily
Executive Summary
Inexperienced users had similar results as experienced operators in the PREVAIL trial of Boston Scientific’s Watchman left-atrial appendage closure device. FDA asked the company to conduct the trial after results of the PROTECT AF trial left doubts about the device’s safety and steep learning curve.
You may also be interested in...
New Products In Brief
Debuts include Medtronic’s next-generation Arctic Front Advance for paroxysmal atrial fibrillation, Covidien’s iDrive Ultra surgical stapler and AngioDynamics’ BioFlo peripherally inserted central catheters.
Research In Brief
Data updates from HRS, SCAI meetings, and more.
Left Atrial Appendage Closure Studies: FDA Offers Tips
The clinical path toward FDA approval of a left atrial appendage closure system for preventing stroke in atrial fibrillation patients has not been simple so far, informing the agency’s current expectations.